We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Majority Leader Steny Hoyer (D-Md.) said House Democrats plan to vote Thursday — or at the latest Friday — on the nearly $2 trillion Build Back Better Act, which contains compromise provisions meant to lower the price of prescription drugs. Read More
Aduhlem is contributing to a 14.5 percent increase in 2022 Medicare Part B premiums, even though the Centers for Medicare and Medicaid Services (CMS) hasn’t yet decided whether it will pay for the controversial Alzheimer’s treatment. Read More
The UK’s National Institute for Health and Care Excellence (NICE) has recommended that the National Health Service (NHS) not offer BioMarin Pharmaceutical’s Vimizim (elosulfase alfa) for treating mucopolysaccharidosis type 4A syndrome, also known as Morquio A syndrome. Read More
Three days before the clock was set to run out on the legality of Janet Woodcock serving as acting commissioner of the FDA, President Biden has announced that he will nominate Robert Califf to take a second turn at occupying the top spot at the agency. Read More
In order to be cost-effective relative to standard Alzheimer’s care, Aduhelm — the newly approved Alzheimer’s antibody — would have to cost no more than $3,000 per year, rather than the current $56,000 price tag. Read More
The European Medicines Agency (EMA) has recommended including transverse myelitis, a rare form of spinal inflammation, to the list of Johnson & Johnson (J&J) COVID-19 vaccine side effects. Read More
Moderna and the National Institutes of Health (NIH) are in a patent dispute over the company’s messenger RNA (mRNA)-based COVID-19 vaccine developed with the aid of government scientists. Read More